Makers of Humira and Enbrel Using New Drug Patents to Delay Generic Versions

Six years after the Affordable Care Act cleared the way for biosimilars, as the generic versions of biotechnology drugs are called, progress has been slow.

from NYT > Health http://ift.tt/29CWa9U
via health&fitness